Cambridge Healthtech Institute’s 10th Annual
Antibodies for Cancer Therapy
Introducing and Optimizing Breakthrough Therapies
May 4-5, 2020
Antibodies have become the most sought-after tools in drug discovery, with bispecific antibodies and cell engagers leading the pack of new constructs. New insights on the tumor microenvironment and the microbiome can determine how successful a therapeutic strategy will be, and new imaging tools will help improve delivery of antibody drugs. The 10th Annual Antibodies for Cancer Therapy conference at PEGS will assemble an all-star roster of speakers to explore current results and learn best practices for moving molecules into the clinic.
IMPROVEMENTS IN TARGETING AND DELIVERY
Discovery and Clinical Translation of ONC201/TIC10
Wafik El-Deiry, MD, PhD, FACP, Associate Dean for Oncologic Sciences, Warren Alpert Medical School, Brown University
Optimization of Antibody Half-Life for Cancer Therapeutics
Donald J. Buchsbaum, PhD, Professor and Director, Division of Radiation Biology, Department of Radiation Oncology, University of Alabama at Birmingham
Selecting the Best Tumor Targets for Imaging
Cornelis F.M. Sier, PhD, Molecular Biologist, Project Leader Targeting, Department of Image-Guided Oncologic Surgery, Leiden University Medical Center
Bispecific Antibodies or TriKEs against a Variety of Solid Tumor Markers
Daniel A. Vallera, PhD, Lion Scholar and Professor, Director, Section on Molecular Cancer Therapeutics; University of Minnesota
Review of Targets and Drug Development Evolution
Arthur Frankel, MD, Chief, Hematology/Oncology, Mitchell Cancer Institute, University of South Alabama
BISPECIFIC ANTIBODIES AND IMMUNOTHERAPY COMBINATIONS
KEYNOTE PRESENTATION: Redirecting T-Cells for Cancer Immunotherapy Using Next-Generation Bispecific Antibodies and Fusion Proteins
Pablo Umaña, PhD, Head, Cancer Immunotherapy Discovery, Roche Innovation Center Zurich (Roche Glycart AG)
FEATURED PRESENTATION: Bispecifics and Beyond: Approaches for Identification of Effective Cancer Therapeutics
Andrew Nixon, PhD, Vice President, Biotherapeutics Molecule Discovery, Boehringer-Ingelheim Pharmaceuticals, Inc.
Assessing Immune Oncology Combinations with Common Light Chain Bispecific Antibodies
Simon Plyte, PhD, Vice President, Immune Oncology, Merus NV
Combinatorial Approaches to Enhance Bispecific Anti-Tumor Efficacy
Eric Smith, PhD, Senior Director, Bispecifics, Regeneron Pharmaceuticals, Inc.
BiSAb T-Cell Engagers that Target Tumor-Specific pMHC Antigens for Solid Tumors
G. Jonah Rainey, PhD, Vice President, Antibody Therapeutics, Gritstone Oncology
TARGETING B7/H3: BRINGING IT FORWARD TO CLINICAL APPLICATION
Talk Title to be Announced
Ezio Bonvini, MD, CSO & Senior Vice President, Research, MacroGenics, Inc.
Novel Approach to Target B7-H3
Soldano Ferrone, MD, PhD, Division of Surgical Oncology, Surgery, Massachusetts General Hospital
BCMA-Directed CAR T Cells for Myeloma: What Have We Learned?
Adam D. Cohen, MD, Assistant Professor, Hematology & Oncology, Perelman Center for Advanced Medicine, University of Pennsylvania
CAR T Cells Targeting CD123 or Other Targets
Terry J. Fry, MD, Professor of Pediatrics, Hematology and Immunology, University of Colorado
Development of Cancer-Reactive Antibodies Focused to the 287-302 Amino Acid Loop of the Human Epidermal Growth Factor Receptor
David J. FitzGerald, PhD, Chief, Biotherapy Section, Laboratory of Molecular Biology, CCR, National Cancer Institute
Glypicans as Emerging CAR T Cell Therapy Targets: GPC3 and Beyond
Mitchell Ho, PhD, Chief, Antibody Therapy Section, Laboratory of Molecular Biology, National Cancer Institute, NIH
* The program is subject to change without notice, due to unforeseen reason.